{
    "clinical_study": {
        "@rank": "14792", 
        "acronym": "PK Combination", 
        "arm_group": [
            {
                "arm_group_label": "Part A1", 
                "arm_group_type": "Active Comparator", 
                "description": "1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), fed 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed"
            }, 
            {
                "arm_group_label": "Part A2", 
                "arm_group_type": "Active Comparator", 
                "description": "1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference) 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed 150 mg ranitidine"
            }, 
            {
                "arm_group_label": "Part B1", 
                "arm_group_type": "Active Comparator", 
                "description": "1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)"
            }, 
            {
                "arm_group_label": "Part B2", 
                "arm_group_type": "Active Comparator", 
                "description": "1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)"
            }, 
            {
                "arm_group_label": "Part B3", 
                "arm_group_type": "Active Comparator", 
                "description": "1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)"
            }
        ], 
        "brief_summary": {
            "textblock": "Study to Assess the Pharmacokinetics of R406 in Healthy Subjects when Fostamatinib 150 mg is\n      Administered Alone in Fed and Fasted state and in Combination with Ranitidine in Fasted\n      State, and to Assess the Relative Bioavailability of Process Variants of Tablets"
        }, 
        "brief_title": "Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Pharmacokinetics", 
        "detailed_description": {
            "textblock": "An Open-label, Single-center, 2-Part, Randomized Study to Assess the Pharmacokinetics of\n      R406 in Healthy Subjects when Fostamatinib 150 mg is Administered Alone in Fed and Fasted\n      state and in Combination with Ranitidine in Fasted State, and to Assess the Relative\n      Bioavailability of Process Variants of Tablets"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provision of signed and dated, written informed consent prior to any study-specific\n             procedures including the genetic sampling and analyses\n\n          -  Volunteers will be males or females aged 18 to 55 years (inclusive) and with a weight\n             of at least 50 kg and body mass index (BMI) between 18 and 30 kg/m2 inclusive.\n\n          -  Provision of signed, written, and dated informed consent for optional genetic\n             research. If a volunteer declines to participate in the genetic component of the\n             study, there will be no penalty or loss of benefit to the volunteer.\n\n          -  Male volunteers should be willing to use barrier contraception, ie, condoms from the\n             day of first dosing until 2 weeks after dosing with the IP in Treatment Period 5.\n\n          -  Females  must have a negative pregnancy test at screening and on admission to the CPU\n             (including check-in at each treatment period), must not be lactating and must be of\n             non childbearing  potential, confirmed at screening\n\n        Exclusion Criteria:\n\n          -  History of any clinically significant disease or disorder which, in the opinion of\n             the Investigator, may either put the volunteer at risk because of participation in\n             the study, or influence the results or the volunteer's ability to participate in the\n             study\n\n          -  History or presence of GI, hepatic, or renal disease or any other condition known to\n             interfere with absorption, distribution, metabolism, or excretion of drugs\n\n          -  Any clinically significant illness, medical/surgical procedure, or trauma within 4\n             weeks of the first administration of IP\n\n          -  Any clinically significant abnormalities in clinical chemistry, hematology, or\n             urinalysis results as judged by the Investigator\n\n          -  Any positive result on screening for serum hepatitis B surface antigen, hepatitis C\n             antibody, and human immunodeficiency virus (HIV)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01682408", 
            "org_study_id": "D4300C00019"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part A1", 
                    "Part A2", 
                    "Part B3"
                ], 
                "description": "1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)", 
                "intervention_name": "Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part A1", 
                    "Part A2"
                ], 
                "description": "3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed", 
                "intervention_name": "Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part B1", 
                "description": "1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)", 
                "intervention_name": "Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part B2", 
                "description": "1 x 150mg mannitol based 38% drug loaded tablet(batch variant B)", 
                "intervention_name": "Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part A2", 
                "description": "150 mg ranitidine", 
                "intervention_name": "Ranitidine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mannitol", 
                "Ranitidine", 
                "Ranitidine bismuth citrate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "R406,", 
            "Fostamatinib,", 
            "Phase I,", 
            "Healthy Subjects,", 
            "Pharmacokinetics,", 
            "Fed/Fasted"
        ], 
        "lastchanged_date": "December 27, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "An Open-label, Single-center, 2-Part, Randomized Study to Assess the Pharmacokinetics of R406 in Healthy Subjects When Fostamatinib 150 mg is Administered Alone in Fed and Fasted State and in Combination With Ranitidine in Fasted State, and to Assess the Relative Bioavailability of Process Variants of Tablets", 
        "overall_official": [
            {
                "affiliation": "Quintiles Phase I unit 6700 w 115th st Overland Park, Ks 66211", 
                "last_name": "Eleanor Lisbon, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "AstraZeneca", 
                "last_name": "Christopher D O'Brien, MD PHD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Pharmacokinetics profile of  R406 in terms of maximum observed plasma concentration (Cmax) and area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC).", 
            "safety_issue": "No", 
            "time_frame": "Day 1 (predose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours postdose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01682408"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetic profile of R406 in terms of area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-t)], time to Cmax (tmax), terminal half-life (t1/2\u03bbz), terminal rate constant (\u03bbz).", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (predose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours postdose"
            }, 
            {
                "measure": "Description of the safety profile in terms of frequency of adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3  - 5 days after discharge"
            }, 
            {
                "measure": "Description of the safety profile in terms of severity of adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "up to  3  - 5 days after discharge"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}